Please select the option that best describes you:
Would you consider a PARPi for a patient with PALB2 mutated metastatic triple negative breast cancer?
If yes, where in sequence would you use it?
Answer from: Medical Oncologist at Academic Institution
PARP inhibitors currently have FDA approval for treatment of breast cancer in patients with HER2 negative disease who carry a BRCA 1 or BRCA 2 mutation, but not other familial (germline) genetic mutations and they are not approved for tumor (acquired) genetic mutations.
Theoretically, PARP in...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Yes, I would consider it given the data from TBCRC-048 showing high response rates to germline PALB2 mutated breast cancer. I would use it in the same sequence as a BRCA1/2 mutated TNBC (after immunotherapy if it was indicated based on the CPS score) if I can get it approved.
Answer from: Medical Oncologist at Community Practice
I would consider it as a later option, especially if toxicity is an issue. The data is still limited in my view (Tung et al., PMID 33119476).